# Insilico Medicine **Source:** https://geo.sig.ai/brands/insilico-medicine **Vertical:** Healthcare Tech **Subcategory:** Drug Discovery & Development **Tier:** Challenger **Website:** insilico.com **Last Updated:** 2026-04-14 ## Summary Insilico Medicine (HKEX: 3696) raised $293M, posted $56.2M revenue in 2025, and inked a $2.75B Eli Lilly deal in 2026 using generative AI to discover drug targets in cancer and CNS. ## Company Overview Insilico Medicine is a clinical-stage biotechnology company founded in 2014 that leverages generative AI for drug discovery and development. Headquartered in Boston with offices in Hong Kong and New York, the company has built AI platforms utilizing deep generative models, reinforcement learning, and transformers to discover novel drug targets and generate molecular structures with desired properties. Its pipeline spans cancer, fibrosis, CNS diseases, infectious diseases, autoimmune conditions, and aging-related diseases. The company operates a dual business model combining internal drug pipeline development with external platform licensing and partnerships. Insilico has secured major collaboration deals valued at billions of dollars with partners including Eli Lilly, Sanofi, Fosun Pharma, Exelixis, and Menarini. Its competitive edge lies in an end-to-end AI platform covering target discovery through clinical candidate nomination, significantly compressing traditional drug development timelines and costs. Insilico listed on the Hong Kong Stock Exchange on December 30, 2025, in the largest biotech IPO on HKEX that year, raising $293M. In March 2026, the company signed a landmark $2.75B agreement with Eli Lilly including a $115M upfront payment. Total 2025 revenue reached $56.2M. With over $393M in cash post-IPO and a robust partnership portfolio valued at over $3.5B collectively, Insilico is positioned as a leading AI-native pharma company. ## Frequently Asked Questions ### What does Insilico Medicine do? Insilico Medicine is a clinical-stage biotech company that uses generative AI platforms to accelerate drug discovery and development across oncology, fibrosis, CNS, infectious diseases, and aging-related conditions. ### Is Insilico Medicine publicly traded? Yes. Insilico Medicine listed on the Hong Kong Stock Exchange (ticker 3696.HK) on December 30, 2025, raising approximately $293 million in its IPO. ### What was Insilico Medicine's revenue in 2025? Insilico Medicine reported total revenue of $56.2 million for the full year 2025. ### Who are Insilico Medicine's major partners? Major partners include Eli Lilly (a $2.75B deal signed in March 2026), Sanofi, Fosun Pharma, Exelixis, and Menarini, with collective partnership values exceeding $3.5 billion. ### When was Insilico Medicine founded? Insilico Medicine was founded in 2014 and is headquartered in Boston, Massachusetts, with additional offices in Hong Kong and New York. ### What are Insilico Medicine's key AI platform components? Insilico's platform has three core components: PandaOmics (target discovery using multi-omics and clinical data), Chemistry42 (generative chemistry for small molecule drug design), and InClinico (clinical trial outcome prediction and patient stratification). Together they form an end-to-end AI-driven pipeline from identifying novel drug targets through to optimizing clinical trial design for candidates entering human studies. ### What is Insilico's lead drug candidate and its significance? ISM001-055 is an AI-designed drug candidate for idiopathic pulmonary fibrosis (IPF) that entered Phase 2 clinical trials — making it one of the world's first drugs with both the target and molecule discovered entirely by AI. Positive Phase 2 results published in 2024 validated Insilico's AI platform for generating clinically active molecules, which was a key milestone for the entire AI drug discovery industry. ### What is the significance of Insilico's Eli Lilly deal? In March 2026, Eli Lilly signed a $2.75 billion partnership with Insilico Medicine — one of the largest AI drug discovery collaborations announced to date. The deal covers multiple therapeutic programs across Lilly's pipeline and validates Insilico's end-to-end AI platform for generating novel drug candidates. The partnership followed Insilico's December 2025 Hong Kong IPO and significantly de-risked the company's financial position while providing Lilly access to Insilico's generative chemistry capabilities at scale. ## Tags b2b, healthtech, saas, public --- *Data from geo.sig.ai Brand Intelligence Database. Updated 2026-04-14.*